Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer

Mok, Tony; Wu, Yi‐Long; Ahn, Myung‐Ju; Chiara Garassino, Marina; Ryun Kim, Hye; S. Ramalingam, Suresh; A. Shepherd, Frances; He, Yong; Akamatsu, Hiroaki; S.M.E. Theelen, Willemijn; Khoon Lee, Chee; Sebastian, Martin; Templeton, Alison; Mann, Helen; Marotti, Marcelo; Ghiorghiu, Serban; A. Papadimitrakopoulou, Vassiliki

doi:10.1056/nejmoa1612674

Public

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

Published in New England Journal of Medicine • Dec 6, 2016

Authors:

Tony Mok

Yi‐Long Wu

Myung‐Ju Ahn

Abstract

BACKGROUND: Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that is selective for both EGFR-TKI sensitizing and T790M resistance mutations in patients with non-small-cell lung cancer. The efficacy of osimertinib as compared with platinum-based therapy plus pem...

Subject

Osimertinib

T790M

Pemetrexed

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!